Switzerland approves Moderna’s COVID-19 vaccine

pharmafile | January 13, 2021 | News story | Research and Development COVID-19, Moderna, Vaccine 

Moderna has announced that its COVID-19 vaccine has been authorised for use on those aged 18 or older in Switzerland.

The authorisation was given by Swissmedic, the Swiss Agency for Therapeutic Products, and was based on a rolling submission of data and the totality of scientific evidence shared by the company, including a data analysis from the pivotal Phase III clinical study announced on November 30. Swissmedic’s approval was also influenced by a recommendation from the Human Medicines Expert Committee, which has authorised the company’s vaccine for use.

The Swiss Federal Government has secured 7.5 million doses of the Moderna jab, and the first deliveries are expected to begin in Switzerland in the next week.

Moderna’s vaccine has also received authorisation from regulatory authorities in the US, Canada, Israel, the EU, and the UK. Additional authorisations are currently under review in other countries and by the WHO.

Stéphane Bancel, Chief Executive Officer of Moderna, said: “Having our COVID-19 vaccine authorised in Switzerland is an important milestone for us.

“Switzerland has played a critical role in Moderna’s history since our early days and it means a lot to us that we can now provide a highly effective vaccine to help protect the citizens of Switzerland.”

Darcy Jimenez

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

FDA approves world’s first RSV vaccine

The US Food and Drug Administration (FDA) has announced that it has approved the world’s …

Latest content